Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients aged ≥ 18 years with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome
Patients on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician
Patients using or willing to use the BETACONNECT autoinjector for Betaferon application
Written informed consent
You may not be if
Patients receiving any other disease modifying drug
Contraindications of Betaferon described in the Summary of Product Characteristics
Patients participating in any other clinical or non-interventional study, evaluating MS therapy
Clareo Health | Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
